Table 4.

Summary of described treatments and models.

Source	Treatment	Method of Action	Effect on Tumor
[73,74]	TARGET database	Prognostic Model	EMGs and lncRNA levels used to assess patient prognosis and the 5-year survival rate
[75]	Immune-related DNAmethylation patterns	Prognostic Model	Methylation patterns associated with drug sensitivities and patient outcomes
[76]	Gemcitabine and epirubicin	Nanoparticle drug delivery	Changes in miRNA expression levels leading to decreased tumor volume
[77]	Genome-wide methylation state	Prognostic Model	Tumor hypomethylation associated with better patient outcomes and a greater response to chemotherapeutics
[78]	DNA methylation probe	Prognostic Model	Probes used to categorize tumors based on the “BRACness” phenotype and assess susceptibility to PARPi
[80]	GSK-J4	UTX inhibitor	Increased H3K27me3 and decreased H3K27ac at LIF, resulting in a defect in stem-cell-like characteristics
[81]	5-Aza	Inhibits DNA methylation	Increased expression of miRNA regulators and decreased expression of ZEB-1
[82]	ALKBH5	Modification of pre-miRNA-181b-1 and YAP	Decreased tumor cell growth, migration, and invasion
[83]	VPA and Hy	Histone deacetylase inhibitor and DNA methylation inhibitor	Induced expression of VEGI/DR3
[84]	GSK343	Histone methyltransferase inhibitor	EZH2 inhibition resulting in induced apoptosis and autophagic cell death
[85]	Berberine	c-Myc modification	Decreased cell proliferation